Table of contents
Menopause
What's new
The American Urological Association (AUA) has issued a new guideline for the management of genitourinary syndrome of menopause, with recommended treatments including local low-dose vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, as well as the use of vaginal moisturizers and/or lubricants and avoidance of vulvovaginal irritants and cleansers. CO₂ laser therapy is considered experimental. .
Background
Overview
Guidelines
Key sources
Screening and diagnosis
Diagnostic investigations
More topics in this section
Evaluation of sexual dysfunction
Evaluation of vaginal bleeding
Cardiovascular risk assessment
Evaluation before hormone therapy
Medical management
More topics in this section
Management of vasomotor symptoms (tibolone)
Management of vasomotor symptoms (non-hormonal therapy)
Considerations for hormone therapy
Management of vulvovaginal atrophy (general principles)
Management of vulvovaginal atrophy (lubricants and moisturizers)
Management of vulvovaginal atrophy (local estrogen therapy)
Management of vulvovaginal atrophy (systemic estrogen therapy)
Management of vulvovaginal atrophy (vaginal laser therapy)
Management of vulvovaginal atrophy (follow-up)
Management of sexual dysfunction
Management of urinary incontinence
Management of recurrent UTI
Management of cardiovascular risks
Management of osteoporosis
Management of cognitive symptoms
Management of depression
Management of sleep disorders
Nonpharmacologic interventions
More topics in this section
Smoking cessation
Alternative medicine
Specific circumstances
More topics in this section
Patients at increased risk of gynecological cancers
Patients with ovarian cancer
Patients with endometrial cancer
Patients with uterine sarcoma
Patients with cervical or vaginal cancer
Patients with vulvar cancer
Patients with breast cancer
Patients with hormone-independent cancer